Prognostic factors in patients with metastatic breast cancer at the time of diagnosis

Pathology Research and Practice

Volumn 210, Issue 5, 2014, Pages 301-306

  Ren, Zhiyong ^a   Li, Yufeng ^b   Hameed, Omar ^a,c   Siegal, Gene P ^a   Wei, Shi ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c Department of Pediatrics   (United States)

Author keywords

Breast cancer; Estrogen receptor; HER2; Progesterone receptor; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADOLESCENT; ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; ARTICLE; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; TREND STUDY; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; BREAST NEOPLASMS; CANCER STAGING; GENETICS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84898057828     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.01.008     Document Type: Article

References (33)

1. Forouzanfar M.H., Foreman K.J., Delossantos A.M., Lozano R., Lopez A.D., Murray C.J., Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011, 378:1461-1484.
2. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J. Clin. 2011, 61:409-418.
3. Chang J., Clark G.M., Allred D.C., Mohsin S., Chamness G., Elledge R.M. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003, 97:545-553.
4. Bendre M., Gaddy D., Nicholas R.W., Suva L.J. Breast cancer metastasis to bone: it is not all about PTHrP. Clin. Orthop. Relat. Res. 2003, S39-S45.
5. Andre F., Slimane K., Bachelot T., Dunant A., Namer M., Barrelier A., Kabbaj O., Spano J.P., Marsiglia H., Rouzier R., Delaloge S., Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J. Clin. Oncol. 2004, 22:3302-3308.
6. Dawood S., Broglio K., Gonzalez-Angulo A.M., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J. Clin. Oncol. 2008, 26:4891-4898.
7. Giordano S.H., Buzdar A.U., Smith T.L., Kau S.W., Yang Y., Hortobagyi G.N. Is breast cancer survival improving?. Cancer 2004, 100:44-52.
8. Cianfrocca M., Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004, 9:606-616.
9. Yamamoto N., Watanabe T., Katsumata N., Omuro Y., Ando M., Fukuda H., Takue Y., Narabayashi M., Adachi I., Takashima S. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J. Clin. Oncol. 1998, 16:2401-2408.
10. Insa A., Lluch A., Prosper F., Marugan I., Martinez-Agullo A., Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res. Treat. 1999, 56:67-78.
11. Jung S.Y., Rosenzweig M., Sereika S.M., Linkov F., Brufsky A., Weissfeld J.L. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 2012, 23:103-112.
12. Largillier R., Ferrero J.M., Doyen J., Barriere J., Namer M., Mari V., Courdi A., Hannoun-Levi J.M., Ettore F., Birtwisle-Peyrottes I., Balu-Maestro C., Marcy P.Y., Raoust I., Lallement M., Chamorey E. Prognostic factors in 1,038 women with metastatic breast cancer. Ann. Oncol. 2008, 19:2012-2019.
13. Lobbezoo D.J., van Kampen R.J., Voogd A.C., Dercksen M.W., van den Berkmortel F., Smilde T.J., van de Wouw A.J., Peters F.P., van Riel J.M., Peters N.A., de Boer M., Borm G.F., Tjan-Heijnen V.C. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res. Treat. 2013, 141:507-514.
14. Wei S., Said-Al-Naief N., Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl. Immunohistochem. Mol. Morphol. 2009, 17:393-402.
15. Hameed O., Adams A.L., Baker A.C., Balmer N.E., Bell W.C., Burford H.N., Chhieng D.C., Jhala N.C., Klein M.J., Winokur T. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. Am. J. Clin. Pathol. 2008, 130:425-427.
16. Nguyen T.L., Grizzle W.E., Zhang K., Hameed O., Siegal G.P., Wei S. Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am. J. Clin. Pathol. 2013, 140:468-474.
17. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S., Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
18. Society A.C. Cancer Facts & Figures 2011 2011, American Cancer Society, Atlanta.
19. Tsuji W., Teramukai S., Ueno M., Toi M., Inamoto T. Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer 2014, 21:86-95.
20. Kawano A., Shimizu C., Hashimoto K., Kinoshita T., Tsuda H., Fujii H., Fujiwara Y. Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. Breast Cancer 2013, 20:145-151.
21. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
22. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
23. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A., Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365:1273-1283.
24. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010, 28:3271-3277.
25. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 2010, 28:92-98.
26. Planchat E., Durando X., Abrial C., Thivat E., Mouret-Reynier M.A., Ferriere J.P., Pomel C., Kwiatkowski F., Chollet P., Nabholtz J.M. Prognostic value of initial tumor parameters after metastatic relapse. Cancer Invest. 2011, 29:635-643.
27. Batina N.G., Trentham-Dietz A., Gangnon R.E., Sprague B.L., Rosenberg M.A., Stout N.K., Fryback D.G., Alagoz O. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res. Treat. 2013, 138:519-528.
28. Stark A., Kleer C.G., Martin I., Awuah B., Nsiah-Asare A., Takyi V., Braman M., Quayson S.E., Zarbo R., Wicha M., Newman L. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 2010, 116:4926-4932.
29. Clarke C.A., Keegan T.H., Yang J., Press D.J., Kurian A.W., Patel A.H., Lacey J.V. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J. Natl. Cancer Inst. 2012, 104:1094-1101.
30. Pacheco J.M., Gao F., Bumb C., Ellis M.J., Ma C.X. Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res. Treat. 2013, 138:281-289.
31. Howard-McNatt M., Lawrence J., Melin S.A., Levine E.A., Shen P. Stewart JHt. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Am. J. Surg. 2013, 205:397-401.
32. Wei S., Li Y., Siegal G.P., Hameed O. Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Ann. Diagn. Pathol. 2011, 15:79-83.
33. Expanded use of Herceptin. FDA Consumer 2007, 41:4-5.